0000000000621560

AUTHOR

Jean-marie R. Frenoux

0000-0002-0593-3825

showing 2 related works from this author

A Polyunsaturated Fatty Acid Diet Lowers Blood Pressure and Improves Antioxidant Status in Spontaneously Hypertensive Rats

2001

gamma-Linolenic acid [GLA, 18:3(n-6)], eicosapentaenoic acid [EPA, 20:5(n-3)] and docosahexaenoic acid [DHA, 22:6(n-3)] have been reported to prevent cardiovascular diseases. However, they are highly unsaturated and therefore more sensitive to oxidation damage. We investigated the effects of a diet rich in these polyunsaturated fatty acids (PUFA) on blood pressure, plasma and lipoprotein lipid concentrations, total antioxidant status, lipid peroxidation and platelet function in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). Five-week-old SHR and WKY rats were fed for 10 wk either a diet containing Isio 4 oil or a diet rich in GLA, EPA and DHA (5.65, 6.39 and…

Lipid Peroxidesmedicine.medical_specialtyTime FactorsAntioxidantDocosahexaenoic AcidsPlatelet AggregationThiobarbituric acidmedicine.medical_treatmentMedicine (miscellaneous)Blood PressureBiologyRats Inbred WKYAntioxidantsLipid peroxidationchemistry.chemical_compoundRats Inbred SHRInternal medicinemedicineAnimalsgamma-Linolenic Acidgamma-Linolenic acidchemistry.chemical_classificationNutrition and DieteticsDietary FatsLipidsEicosapentaenoic acidRatsEndocrinologyEicosapentaenoic AcidchemistryDocosahexaenoic acidHypertensionFatty Acids Unsaturatedlipids (amino acids peptides and proteins)LipoproteinPolyunsaturated fatty acidThe Journal of Nutrition
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct